Integrated Epigenetic and Transcriptomic Analysis Identifies Interleukin 17 DNA Methylation Signature of Malignant...

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• Sarcomas are aggressive, metastatic tumors with over 100 subtypes, posing challenges for outcome prediction.
• Developing multisarcoma signatures is difficult due to tumor diversity and rarity.

Purpose of the Study:

• To identify a DNA methylation signature for sarcoma progression and metastasis across multiple subtypes.
• To investigate the role of PRC2 loss in Malignant Peripheral Nerve Sheath Tumor (MPNST) metastasis and DNA methylation.

Main Methods:

• Utilized multiple epigenetic and genomic patient datasets to identify DNA methylation patterns.
• Analyzed hypermethylated CpGs in MPNSTs with PRC2 loss.
• Correlated differentially methylated CpGs in the IL17D/RD family with MPNST progression and metastasis using independent datasets.

Main Results:

• Over 900 CpGs were hypermethylated in MPNSTs lacking PRC2.
• Eight differentially methylated CpGs in the IL17D/RD family were identified, correlating with MPNST progression and metastasis.
• Similar methylation trends were observed in osteosarcoma, rhabdomyosarcoma, and synovial sarcoma; IL17D/RD expression was detected in tumor and stromal cells.

Conclusions:

• The identified DNA methylation signature has potential implications for sarcoma clinical management.
• This signature could aid in the surveillance of sarcoma patients, particularly those with MPNSTs.